A group of researchers from the University of Erlangen in Germany [10, 11, 13, 15, 30–33] published several case reports using a CAR-T against CD19 as a compassionate therapy in SLE initially and then extending to systemic sclerosis and inflammatory myopathy. Here, CD19 is linked to systemic sclerosis.